OphtahliX Inc.
AboutSciencePipelineInvestor InformationContact
About Ophthalix About Ophthalix About Ophthalix About Ophthalix About Ophthalix

OphthaliX Inc. (OTCBB:OPLI) is an advanced clinical-stage biopharmaceutical company focused on developing therapeutic products for the treatment of ophthalmic disorders. OphthaliX drug candidate, CF101, an A3 adenosine receptor agonist, is a novel first in class small molecule orally bioavailable drug, which is being developed to treat three ophthalmic indications: dry eye syndrome; glaucoma and uveitis.

Science

The company technology platform is based on the finding that the Gi protein coupled A3 adenosine receptor (A3AR) is highly expressed in inflammatory cells whereas low expression is found in normal body cells. High A3AR expression >>  more...

Pipeline

CF101 is currently being developed by OphthaliX to treat three ophthalmic indications: dry eye syndrome; glaucoma and uveitis. A phase III dry eye syndrome study is currently ongoing, under a US IND, in the US, Europe  >> more...


News

31/12/2013
OphthaliX to Conduct a Retrospective Analysis of the Phase III Dry Eye Syndrome Study Data Based on the A3 Adenosine Receptor Biomarker>> more...
30/12/2013
OphthaliX Announces Top-Line Results of Phase III Study with CF101 for Dry Eye Syndrome>> more...